SAN DIEGO, Aug. 3, 2023 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural killer cells (iNK) and macrophages (iMACs), today announced that it will participate in the 2023 Wedbush Pacgrow Healthcare Conference taking place August 8-9, 2023 in New York, NY. 

Kleanthis G. Xanthopoulos, Ph.D., Shoreline’s Chairman and CEO, will participate on a cell therapy panel on Tuesday, August 8, 2023 at 8am ET with 2Seventy Bio, Artiva and TScan Therapeutics.  Shoreline management will also participate in one-on-one meetings with investors during the conference.

About Shoreline Biosciences

Shoreline Biosciences is a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural killer cells (iNK) and macrophages (iMACs). The company’s cellular design and gene editing technologies are built on a unique understanding of iPSC differentiation, immune cell biology and premier gene editing tools such as SLEEK knock-in technology and access to AsCas12a, a high fidelity and high efficiency engineered CRISPR/CAS endonuclease. Our allogeneic effector cells are designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. 

For more information, please visit https://shorelinebio.com/ and engage with us on LinkedIn.

SAN DIEGO, March 16, 2023 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms, today announced the presentation of preclinical data at the American Association for Cancer Research (AACR) annual meeting taking place in Orlando, FL, from April 14-19, 2023.

Details of the Shoreline poster are below:

Title: “A novel method for clinical scale production of natural killer cells from clonal master induced pluripotent stem cells with CISH knockout for next generation, off-the-shelf cancer immunotherapy”
Session Category: Immunology
Session Title: Natural Killer and Natural Killer T Cell-based Cellular Therapies
Session Date and Time: Monday April 17, 2023, 1:30 PM – 5:00 PM
Location: Poster Section 22
Abstract Number: 2919

Abstracts and full session details can be accessed through the AACR meeting planner: AACR Annual Meeting 2023 | Meetings | AACR

About Shoreline Biosciences

Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company’s cellular design technologies are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACs as allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA. 

For more information, please visit https://shorelinebio.com/ and engage with us on LinkedIn.

SAN DIEGO, March 16, 2023 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms, today announced the presentation of preclinical data at the American Association for Cancer Research (AACR) annual meeting taking place in Orlando, FL, from April 14-19, 2023.

Details of the Shoreline poster are below:

Title: “A novel method for clinical scale production of natural killer cells from clonal master induced pluripotent stem cells with CISH knockout for next generation, off-the-shelf cancer immunotherapy”
Session Category: Immunology
Session Title: Natural Killer and Natural Killer T Cell-based Cellular Therapies
Session Date and Time: Monday April 17, 2023, 1:30 PM – 5:00 PM
Location: Poster Section 22
Abstract Number: 2919

Abstracts and full session details can be accessed through the AACR meeting planner: AACR Annual Meeting 2023 | Meetings | AACR

About Shoreline Biosciences

Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company’s cellular design technologies are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACs as allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA. 

For more information, please visit https://shorelinebio.com/ and engage with us on LinkedIn.

SAN DIEGO, Feb. 21, 2023 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms, today announced the appointment of Mauro P. Avanzi, M.D., Ph.D. as Chief Medical Officer.

Dr. Avanzi is an experienced physician-scientist and hematologist/oncologist with over fifteen years of clinical experience, including over ten years of experience advancing cellular therapies through early and late-stage of development.  In his new role, Dr. Avanzi will be responsible for leading and expanding Shoreline’s clinical portfolio and will serve as a key member of its Executive team.

“We are extremely pleased that Mauro is joining Shoreline at such a pivotal time in the growth of our company.  Mauro is a recognized immuno-oncology expert with a wealth of expertise in leading cross-functional clinical teams that have advanced important cellular therapies through all stages of development, including commercial approval in global markets,” said Kleanthis G. Xanthopoulos, Ph.D., Shoreline’s Chairman and CEO. “Mauro’s unique background and proven track record in cell therapy will strengthen our capabilities as we bring next-generation immunotherapies to patients with cancer.”

Prior to joining Shoreline, Dr. Avanzi served as Vice President, Clinical Development at Neogene Therapeutics (acquired by AstraZeneca), where he was responsible for leading clinical studies with TCR T cells targeting neoantigens.  Prior to Neogene, Dr. Avanzi held a number of positions of increasing responsibility at Kite Pharma (acquired by Gilead), where he supported multiple clinical programs through all stages of development.  Dr. Avanzi has extensive clinical development experience  in both the US and EU, and has played an integral role in multipe IND/CTA and sBLA filings, including the commercial approval of Yescarta for indolent NHL.  Dr. Avanzi earned his M.D. at Campinas Medical School (Puc) in Brazil and completed an internal medicine residency and hematology/oncology fellowship at the São Paulo University (USP). He completed his Ph.D. research at the New York Blood Center/Santa Casa Medical School and a post-doctoral fellowship focusing on CAR-T cells at Memorial Sloan Kettering Cancer Center.  Dr. Avanzi is an author of multiple peer-reviewed publications on adoptive cellular therapies. 

Dr. Avanzi commented, “I have long admired Shoreline’s focus and leadership position in cell therapy and I am very excited about the clinical potential of the Shoreline pipeline. I believe that Shoreline has the strongest set of tools to win the war on cancer, including its industry-leading iPSC derived iNK and iMAC platforms and the recent addition of key gene-editing and manufacturing technologies. The company’s deep expertise in iPSC differentiation, immune cell biology, and gene-editing make this an opportunity that I find very compelling, and I look forward to building a meaningful clinical portfolio that will deliver therapeutic benefit to patients.”

About Shoreline Biosciences

Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company’s cellular design technologies are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACs as allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA. 

For more information, please visit https://shorelinebio.com/ and engage with us on LinkedIn.

Investor Contact:
Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243

Media Contact:
David Schull
Russo Partners
David.Schull@russopartnersllc.com  
212-845-4271

SOURCE Shoreline Biosciences, Inc.

• Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and  a non-exclusive license for AsCas12a

• Shoreline to acquire Editas Medicine’s iNK cell franchise, including EDIT-202 and certain related manufacturing technologies

• Economics to Editas Medicine to include upfront payment, and development and commercial milestone and royalty payments

CAMBRIDGE, Mass. And SAN DIEGO, Jan. 19, 2023 – Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it has entered into a definitive agreement with Shoreline Biosciences (Shoreline) for Shoreline to license Editas Medicine’s proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies and acquire Editas Medicine’s preclinical gene edited induced pluripotent stem cell (iPSC) derived natural killer cell (iNK) programs and related manufacturing technologies.

Shoreline Biosciences is a private biopharmaceutical company developing next-generation cellular immunotherapies based on iPSCs utilizing proprietary iNK and macrophage (iMACs) platforms.

Under the terms of the agreement, Shoreline will obtain an exclusive license to Editas Medicine’s interest in SLEEK gene editing knock-in technology for use in Shoreline’s iNK platform and for oncology in its iMACs platform, and on a non-exclusive basis for iMACs in other indications. Shoreline will also receive a non-exclusive license for the use of Editas Medicine’s engineered AsCas12a enzyme.

As part of the transaction, Shoreline will acquire EDIT-202, Editas Medicine’s preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors, as well as an additional iNK program under development and certain related manufacturing technologies. The acquisition of the Company’s wholly owned oncology assets by Shoreline is part of Editas Medicine’s strategic portfolio reprioritization, including its focus on the development of in vivo gene edited medicines.

“The acquisition of our allogeneic iNK franchise by Shoreline is highly aligned with our strategic portfolio reprioritization, as it allows us to sharpen our efforts on advancing current clinical stage trials and focus our resources on in vivo fit-for-purpose therapeutic construction and development.” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. “Shoreline is a leader in developing next generation iNK and macrophage cell therapies, and we believe they are the right company to move these assets toward clinical applications.”

“Our goal is to win the war on cancer, and through this agreement with Editas, we have strategically enhanced our ability to execute upon our mission.  The addition of Editas Medicine’s novel gene editing SLEEK technology, combined with the use of a high efficiency and high fidelity proprietary CRISPR enzyme, and the other assets from Editas Medicine’s iNK franchise, strengthens our portfolio and ability to create next generation immunotherapies for patients with cancer,” said Kleanthis G. Xanthopoulos, Ph.D., Shoreline’s Chairman and CEO, Shoreline Biosciences. “We look forward to advancing our pipeline towards the clinic, including these new assets and technologies from Editas.”

Shoreline will pay Editas Medicine an upfront payment at the close of the transaction. Additionally, Editas Medicine is eligible to receive future development and commercial milestone and royalty payments for each of the iNK programs and for future programs engineered with the gene editing technologies. Evercore Group LLC served as financial advisor to Editas Medicine on the transaction.

About Editas Medicine

As a clinical-stage genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute and Harvard University’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

About Shoreline Biosciences

Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company’s cellular design technologies are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACs as allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA. 

Editas Medicine Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the expected benefits of Editas Medicine’s transaction with Shoreline, including any future payments it may receive under the agreement and the impact on its strategic portfolio reprioritization. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials, and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

###

Editas Medicine Contacts:

Media

Cristi Barnett

(617) 401-0113

cristi.barnett@editasmed.com

Investors

Ron Moldaver

(617) 401-9052

ir@editasmed.com

Shoreline Biosciences Contacts:

Investor Contact

Amy Conrad

Juniper Point

amy@juniper-point.com

858-366-3243

Media Contact

David Schull

Russo Partners

David.Schull@russopartnersllc.com 

212-845-4271

SAN DIEGO, Dec. 5, 2022 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms, today announced that it will present new data on its iNK platform during an oral presentation and in a poster at the annual meeting of the American Society of Hematology 2022 (ASH 2022).  ASH 2022 will be held from Saturday, December 10, to Tuesday, December 13, 2022, in New Orleans, Louisiana.

During the oral presentation, Shoreline scientists will showcase the Company’s novel manufacturing process to support the clinical scale cGmP production of CISH knock-out iNK cells. 

“We are thrilled to showcase Shoreline’s CISH knock-out engine and our scalable manufacturing approach during our presentations at ASH 2022,” said Kleanthis G. Xanthopoulos, Ph.D., Shoreline’s Co-Founder, Chairman and CEO.  “We believe our approach holds tremendous potential to create next-generation products using iNKs that reduce the cost and complexity of conventional cell therapy approaches.” 

Robert Hollingsworth, Ph.D., Shoreline’s Chief Scientifc Officer, added, “Our goal is to win the war on cancer with our iPSC-derived iNK and iMACs and presenting our scientific progress to our peers and collaborators is crucial to Shoreline’s growth.  We want to thank the organizers at ASH for recognizing Shoreline and providing us with the opportunity to highlight our science and we look forward to advancing our pipeline towards the clinic.”

Details of the Shoreline presentations are below:

Oral Presentation:

Title: “A Novel Method for Efficient cGMP Production of Natural Killer Cells from Clonal Master Induced Pluripotent Stem Cells for Next Generation, Off-the-Shelf Cancer Immunotherapy”
Session Name: 711. Cell Collection and Processing I
Session Date: Sunday, December 11, 2022
Session Time: 4:30 PM – 6:00 PM
Presentation Time: 5:45 PM
Room: Ernest N. Morial Convention Center, 220-222

Authors: Davide Bernareggi, Caryn Gonsalves, Max Schabla, Alejandra Gárate-Carrillo, Mohammad El-Kalay, Dan S. Kaufman, Robert Hollingsworth, Huang Zhu

Poster Presentation:

Title: “Development of Next-Generation NK Cell Optimized Chimeric Antigen Receptors (CARs) for iPSC-Derived NK Cell Therapies Targeting Both Solid and Liquid Tumors”

Session Name: 703. Cellular Immunotherapies: Basic and Translational: Poster I
Session Date: Saturday, December 10, 2022
Presentation Time: 5:30 PM – 7:30 PM
Location: Ernest N. Morial Convention Center, Hall D

Authors:  Lee Swanson, PhD, Kenyon Lyon, Wael Tadros, PhD, Mafalda Loreti,PhD, Tammy Babin, Benjamin Blair, Max Schabla, PhD, Paschalis Sideras, PhD, Dan S Kaufman, MD, PhD, Robert Hollingsworth, PhD and Huang Zhu

The abstracts are available on ASH’s official website.

About Shoreline Biosciences

Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company’s cellular design technologies are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACs as allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA. 

SAN DIEGO, Oct. 24, 2022 / — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms, today announced the appointment of Charles Calderaro III as Chief Technical Officer. Mr. Calderaro brings three decades of manufacturing and engineering experience to Shoreline, with industry-leading expertise in building and optimizing technical and manufacturing infrastructures for cell therapy products.

“Chuck is a drug manufacturing expert, highlighted by the successful creation and implementation of end-to-end manufacturing and commercial operations for Kite, a Gilead company and a leading cell therapy company. I am thrilled to welcome him to Shoreline as Chief Technical Officer,” said Kleanthis G. Xanthopoulos, Ph.D., Shoreline’s Co-Founder, Chairman and CEO. “With Chuck’s expertise and our iPSC platforms, we are well positioned to implement our planned scalable manufacturing approach, designed to reduce the cost and complexity of manufacturing and enable the development of true ‘off-the-shelf’ products for use in outpatient settings. This could lead to a significant competitive advantage as we move our iNKs and iMACs towards the clinic.”

Prior to joining Shoreline, Mr. Calderaro served as Global Head of Technical Operations for Kite, a pioneer in cell therapy development, where he was responsible for leading all aspects of Kite’s technical operations, including process development, CMC regulatory, manufacturing, quality, supply chain, engineering, and end-to-end optimization of commercial and pipeline products. While at Kite, Mr. Calderaro oversaw the manufacturing of CAR-T cell therapy products at commercial scale. Prior to Kite, Mr. Calderaro was Senior Vice President, Global Manufacturing at BioMarin Pharmaceutical, where he was responsible for the strategic oversight and leadership of a diverse international manufacturing network, which utilizes small molecule, oligonucleotide, biotechnology, and gene therapy technologies to deliver an innovative portfolio of clinical and commercial products to patients. Before that, he spent fourteen years at Genentech in roles of increasing responsibility in product management, engineering, and manufacturing. Early in his career, Mr. Calderaro spent time at Alcon, a division of Novartis, and at Aventis Behring, spanning roles in manufacturing, validation, and biopharmaceutical operations. Mr. Calderaro received a Bachelor’s degree, Electrical Engineering from the University of Notre Dame, a Master’s Degree, Nuclear Engineering from the US Naval Nuclear Power School and a Master of Business Administration from Texan Christian University.

“It is clear that a major gating factor to increasing the number of cellular immunotherapies on the market is the lack of automation in the manufacturing process. Shoreline’s smart manufacturing system holds tremendous promise to create a novel, scalable, end-to-end process, that will optimize the product quality of iPSC-derived cell therapies,” added Mr. Calderaro. “The strength of the technology and the team created a compelling opportunity for me and I look forward to creating the manufacturing system of the future, with the goal of finally winning the war on cancer and delivering benefit to patients.”

Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company’s cellular design technologies are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACs as allogeneic “off-the-shelf” cellular immunotherapies designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA.